Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda + Herceptin + Chemo in HER2+ Gastric Cancer
NCT02901301Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Feb 2017
- Primary completion
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in gastric cancer (GC), sponsored by Yonsei University. Primary endpoints: Recommended Phase 2 Dose at 4 weeks and Overall Response Rate at 6 weeks. Status: unknown.
02
Drugs
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02901301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02901301.